McNicoll Lewis & Vlak Starts OraSure Technologies (OSUR) at Buy, Positive Up Coming Quarters
Tweet Send to a FriendGet Alerts OSUR Hot Sheet
Price: $4.34 -1.59%
Rating Summary:
11 Buy, 2 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 18 | New: 13
Rating Summary:
11 Buy, 2 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 18 | New: 13
Trade OSUR Now!
McNicoll Lewis & Vlak initiates coverage on shares of OraSure Technologies (NASDAQ: OSUR) with a Buy rating and believes that $10 is a fair valuation.
The company is currently putting its efforts forth to enter new markets in infectious diseases rapid testing and oral-fluid based substance abuse testing.
The firm believes that OSUR is poised for growth over several markets as it has partnerships with major pharmaceutical and diagnostics companies like Merck & Co. (NYSE: MRK) and Roche.
McNicoll Lewis & Vlak thinks that OraSure’s HIV OTC test will be approved in 2012 and sees testing volumes in the HCV market increasing. The firm comments that, "Additionally in 2012, we think that Roche and OraSure will work to increase market adoption of oral fluid drug testing assays. We expect to see incremental news regarding each of these value drivers over the next 12 months.
For more ratings news on OraSure Technologies click here and for the rating history of OraSure Technologies click here.
Shares of OraSure Technologies closed at $7.56 yesterday, with a 52 week range of $3.18-$7.66.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
The company is currently putting its efforts forth to enter new markets in infectious diseases rapid testing and oral-fluid based substance abuse testing.
The firm believes that OSUR is poised for growth over several markets as it has partnerships with major pharmaceutical and diagnostics companies like Merck & Co. (NYSE: MRK) and Roche.
McNicoll Lewis & Vlak thinks that OraSure’s HIV OTC test will be approved in 2012 and sees testing volumes in the HCV market increasing. The firm comments that, "Additionally in 2012, we think that Roche and OraSure will work to increase market adoption of oral fluid drug testing assays. We expect to see incremental news regarding each of these value drivers over the next 12 months.
For more ratings news on OraSure Technologies click here and for the rating history of OraSure Technologies click here.
Shares of OraSure Technologies closed at $7.56 yesterday, with a 52 week range of $3.18-$7.66.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Deutsche Bank Starts Kodiak Oil & Gas (KOG) at Hold
- Stifel Nicolaus Starts LKQ Corp. (LKQ) at Buy
- UPDATE: MKM Partners Downgrades Alkermes (ALKS) to Sell
Create E-mail Alert Related Categories
New Coverage
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
